Comparing VTE risks of various hormone formulations
Women who use oral contraceptives (OC) or hormone replacement therapy (HRT) have a two- to sixfold increased risk of a venous thromboembolic event (VTE) compared with nonusers, according to a recent review of available data. Users of OCs containing desogestrel or gestodene, as opposed to levonorgestrel, are at slightly higher risk. And users of OCs or HRT who carry an inherited hypercoaguable state are at exponentially higher risk.
Women who use oral contraceptives (OC) or hormone replacement therapy (HRT) have a two- to sixfold increased risk of a venous thromboembolic event (VTE) compared with nonusers, according to a recent review of available data. Users of OCs containing desogestrel or gestodene, as opposed to levonorgestrel, are at slightly higher risk. And users of OCs or HRT who carry an inherited hypercoaguable state are at exponentially higher risk.
Of the combination OCs, those containing 35 µg or less of ethinyl estradiol and a second-generation progestin are associated with the lowest risk of VTEs. But the safest option, in terms of lowest risk of VTE, may be progestin-only contraceptives and transdermal HRT.
Interestingly, the true VTE risk associated with norethindrone and norgestimate-among the most commonly used progestins in the US-is essentially unknown.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
